Post by lakers on Feb 12, 2016 10:37:14 GMT -5
Catalyst's
1) Cash Raised
2) Receptor Life Sciences Partnership Transparency
3) Sanofi Settlement Agreement Announced
4) Mannkind Commercialization Strategy Announced
5) Mannkind Afrezza North America Partnership (s) Distribution Agreements Announced
6) New Chief Commercial Sales & Marketing Executive Hire Announced
7) Mannkind New Commercialization Organization Strategy Announced
8) Afrezza Regulatory Filings Announced Outside The United States
9) Afrezza Partnership (s) & Distribution Agreement Announced Outside The United States
10) Afrezza Licensing Deals With Countries Recognizing FDA Approval Announced
11) New Technosphere External R&D Licensing Deals Announced
12) New Technosphere Internal R&D Partnership Deals Announced
13) Possible Afrezza Asset Sale Announcement
14) 2 Completed REMS Positive Clinical Trial Results Announced @ ADA Meeting June
15) Mannkind Announced New Pricing Strategy For Afrezza
16) Mannkind Pursuing Ultra-Rapid Acting Label Outside The United States
17) Mannkind Pursuing Ultra-Rapid Acting Updated Label In The United States
18) Mannkind Announces Partnership & Regulatory Status In North & Sough America
19) FDA Analysis Of Real World Data Reports No New Safety or Side Effects Associated With Afrezza
20) Wall Street Analysis Begin Upgrading Mannkind Including Goldman Sachs
21) Mannkind Announces Successfully Negotiating Debt Restructuring
finance.yahoo.com/mbview/threadview/?&bn=0243242e-59fb-3abc-8d27-962c7bf26a1d&tid=1455289990058-98b52599-dbd6-4d99-800c-fdb444abdbc6&tls=la%2Cd%2C2%2C3
Mannkind has joint patents with Technovax & Rose Pharmaceutical who respectively each have licensing deals with Pfizer & Lilly. See below:
Mannkind & Technovax & Pfizer:
"TechnoVax Licenses Wyeth's Virus-Like Particle Vaccine Technology
TechnoVax gained the rights to Wyeth’s patent application in the field of virus-like particle (VLP) technology. This application is based on research conducted by TechnoVax founder, Jose M. Galarza, Ph.D., while serving as principal scientist at Wyeth."
"Pub. No.: WO/2014/066856
Publication Date: 01.05.2014
INHALABLE INFLUENZA VACCINE COMPOSITIONS AND METHODS
Applicants: MANNKIND CORPORATION [US/US]; 28903 North Avenue Paine Valencia, CA 91355 (US).
TECHNOVAX, INC. [US/US]; 765 Old Saw Mill River Road Tarrytown, NY 10591 (US)
Inventors: SMUTNEY, Chad, C.; (US). -LEONE-BAY, Andrea; (US) - GALARZA, Jose, M.; (US) -. MUNOZ, Hector; (US). - MARTIN, George, R.; (US). GRANT, Marshall, L.; (US):"
----------------------------------------------------------------------------------------------------------------------
Mannkind + Rose Pharma + Lilly:
"Rose Pharma signed an agreement with Eli Lilly and Company (Indianapolis, USA) to in-license a Lilly compound (formerly known as LY307161, now named ROSE-010), an analogue of the naturally occurring intestinal hormone GLP-1. The licensing agreement is a result of an ongoing research collaboration the two companies have participated in since 2004."
"Publication Number: 20140187490
Publication Date: 03.07.2014
GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome
Applicants: Rose Pharma A/S & MannKind Corporation
Inventors: Richardson Peter - Kenny Edna - Hellstrom Per - Grant Marshall L. - Stowell Grayson W.
Daniels Scott - Smithson Anthony - Greene Stephani"
finance.yahoo.com/mbview/threadview/;_ylt=AkOoYoXKnb0vCOqg_SxpnQjeAohG;_ylu=X3oDMTB2cjZ1YzF1BHBvcwMzNwRzZWMDTWVkaWFNc2dCb2FyZHNYSFJVbHQ-;_ylg=X3oDMTBhYWM1a2sxBGxhbmcDZW4tVVM-;_ylv=3?&bn=0243242e-59fb-3abc-8d27-962c7bf26a1d&tid=1455285590788-ead74118-8920-4d28-8ece-46d0639546e3&tls=la%2Cd%2C6%2C3
Don't forget Mannkind's joint patent with Technovax for vaccines that could be used for a wide array of vaccine treatments. Technovax licensed the VLP Technology that they are now combining with Mannkind's Technosphere & Drug Deliver Device Platform from Wyeth that is now part of Pfizer. Pfizer has a huge vaccine program that could eventually involve Mannkind. Lots going on behind the scenes for a long time that hopefully will soon be transparent by Mannkind.
1) Cash Raised
2) Receptor Life Sciences Partnership Transparency
3) Sanofi Settlement Agreement Announced
4) Mannkind Commercialization Strategy Announced
5) Mannkind Afrezza North America Partnership (s) Distribution Agreements Announced
6) New Chief Commercial Sales & Marketing Executive Hire Announced
7) Mannkind New Commercialization Organization Strategy Announced
8) Afrezza Regulatory Filings Announced Outside The United States
9) Afrezza Partnership (s) & Distribution Agreement Announced Outside The United States
10) Afrezza Licensing Deals With Countries Recognizing FDA Approval Announced
11) New Technosphere External R&D Licensing Deals Announced
12) New Technosphere Internal R&D Partnership Deals Announced
13) Possible Afrezza Asset Sale Announcement
14) 2 Completed REMS Positive Clinical Trial Results Announced @ ADA Meeting June
15) Mannkind Announced New Pricing Strategy For Afrezza
16) Mannkind Pursuing Ultra-Rapid Acting Label Outside The United States
17) Mannkind Pursuing Ultra-Rapid Acting Updated Label In The United States
18) Mannkind Announces Partnership & Regulatory Status In North & Sough America
19) FDA Analysis Of Real World Data Reports No New Safety or Side Effects Associated With Afrezza
20) Wall Street Analysis Begin Upgrading Mannkind Including Goldman Sachs
21) Mannkind Announces Successfully Negotiating Debt Restructuring
finance.yahoo.com/mbview/threadview/?&bn=0243242e-59fb-3abc-8d27-962c7bf26a1d&tid=1455289990058-98b52599-dbd6-4d99-800c-fdb444abdbc6&tls=la%2Cd%2C2%2C3
Mannkind has joint patents with Technovax & Rose Pharmaceutical who respectively each have licensing deals with Pfizer & Lilly. See below:
Mannkind & Technovax & Pfizer:
"TechnoVax Licenses Wyeth's Virus-Like Particle Vaccine Technology
TechnoVax gained the rights to Wyeth’s patent application in the field of virus-like particle (VLP) technology. This application is based on research conducted by TechnoVax founder, Jose M. Galarza, Ph.D., while serving as principal scientist at Wyeth."
"Pub. No.: WO/2014/066856
Publication Date: 01.05.2014
INHALABLE INFLUENZA VACCINE COMPOSITIONS AND METHODS
Applicants: MANNKIND CORPORATION [US/US]; 28903 North Avenue Paine Valencia, CA 91355 (US).
TECHNOVAX, INC. [US/US]; 765 Old Saw Mill River Road Tarrytown, NY 10591 (US)
Inventors: SMUTNEY, Chad, C.; (US). -LEONE-BAY, Andrea; (US) - GALARZA, Jose, M.; (US) -. MUNOZ, Hector; (US). - MARTIN, George, R.; (US). GRANT, Marshall, L.; (US):"
----------------------------------------------------------------------------------------------------------------------
Mannkind + Rose Pharma + Lilly:
"Rose Pharma signed an agreement with Eli Lilly and Company (Indianapolis, USA) to in-license a Lilly compound (formerly known as LY307161, now named ROSE-010), an analogue of the naturally occurring intestinal hormone GLP-1. The licensing agreement is a result of an ongoing research collaboration the two companies have participated in since 2004."
"Publication Number: 20140187490
Publication Date: 03.07.2014
GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome
Applicants: Rose Pharma A/S & MannKind Corporation
Inventors: Richardson Peter - Kenny Edna - Hellstrom Per - Grant Marshall L. - Stowell Grayson W.
Daniels Scott - Smithson Anthony - Greene Stephani"
finance.yahoo.com/mbview/threadview/;_ylt=AkOoYoXKnb0vCOqg_SxpnQjeAohG;_ylu=X3oDMTB2cjZ1YzF1BHBvcwMzNwRzZWMDTWVkaWFNc2dCb2FyZHNYSFJVbHQ-;_ylg=X3oDMTBhYWM1a2sxBGxhbmcDZW4tVVM-;_ylv=3?&bn=0243242e-59fb-3abc-8d27-962c7bf26a1d&tid=1455285590788-ead74118-8920-4d28-8ece-46d0639546e3&tls=la%2Cd%2C6%2C3
Don't forget Mannkind's joint patent with Technovax for vaccines that could be used for a wide array of vaccine treatments. Technovax licensed the VLP Technology that they are now combining with Mannkind's Technosphere & Drug Deliver Device Platform from Wyeth that is now part of Pfizer. Pfizer has a huge vaccine program that could eventually involve Mannkind. Lots going on behind the scenes for a long time that hopefully will soon be transparent by Mannkind.